Annotation Detail
Information
- Associated Genes
- CD274
- Associated Variants
-
CD274 EXPRESSION
CD274 EXPRESSION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1733
- Gene URL
- https://civic.genome.wustl.edu/links/genes/11335
- Variant URL
- https://civic.genome.wustl.edu/links/variants/276
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Pembrolizumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 27718847
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Pembrolizumab | Sensitivity | true |